In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $5.00 price target on XOMA Corp. NASDAQ.
In the report, Credit Suisse noted, "We anticipate that the final event in the EYEGUARD B trial will occur soon, and this will trigger an approximate six-week clock to top-line data release. Newly announced positive data in scleritis is encouraging and points to continued activity of gevokizumab across different inflammatory indications. Our 2015 EPS decreases to ($0.55) from ($0.50) based on 2015 guidance."
XOMA closed on Wednesday at $3.72.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in